<DOC>
	<DOCNO>NCT00624832</DOCNO>
	<brief_summary>This study intend demonstrate patient standard high immunoglobulin E ( IgE ) level protect allergen induced broncho-constriction Xolair</brief_summary>
	<brief_title>A Study Efficacy New Doses Xolair Protect From Allergen Challenge Groups Asthma Patients Defined IgE Levels</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin E</mesh_term>
	<criteria>Male female adult patient , body weight 40150 kg age 1865 year ( inclusive ) Patients diagnose asthma Forced Expiratory Volume ( FEV1 ) â‰¥65 % predict normal value patient Positive skin prick test specific allergen Patients demonstrate Provocative Dose 20 % FEV1 decline ( PD20 ) response aeroallergen grade allergen bronchoprovocation test ( ABP ) screen Current active smoker Patients hospitalized emergency treatment asthma attack 12 month prior study start History bleeding disorder History drug allergy Pregnant woman nurse mother Females childbearing potential , regardless whether sexually active , use reliable form contraception ( surgical contraception double barrier method ( continue least two month follow last dose ) acceptable ) . Sexually active male sterilize use condom History immunocompromise , include positive HIV A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month study start Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>allergen challenge</keyword>
	<keyword>bronchoprovocation</keyword>
	<keyword>Methacholine challenge</keyword>
	<keyword>serum Immunoglobulin E</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>skin prick test</keyword>
</DOC>